肾上腺功能不全中FKBP5甲基化:评估糖皮质激素替代质量的新视角
该横断面探索性研究分析了120例慢性原发性或继发性肾上腺功能不全患者接受氢化可的松替代治疗时FKBP5基因54个CpG位点的甲基化水平,发现甲基化与GC剂量、临床评分及唾液和尿皮质醇呈负相关,且被建议增加剂量的患者甲基化更高,提示FKBP5甲基化可能反映GC替代的剂量依赖性效应。
要点
- FKBP5甲基化与氢化可的松剂量、临床GC替代评分及唾液/尿皮质醇呈负相关。
- 被建议增加GC剂量的患者FKBP5甲基化水平高于建议减量或维持者。
- AI患者FKBP5甲基化水平与CPA患者相似或更低,提示传统GC治疗的皮质醇峰值可能影响甲基化。
核心结论
- FKBP5甲基化状态与GC替代剂量及临床治疗评估相关,提示GC替代对FKBP5甲基化有剂量依赖性效应。
- AI患者相比CPA患者甲基化水平更低,提示传统GC治疗下的皮质醇峰值可能影响FKBP5甲基化。
研究设计与样本
- 探索性横断面分析,纳入120例慢性原发性(n=72)和继发性(n=48)肾上腺功能不全患者,均接受氢化可的松替代治疗。
- 采用亚硫酸氢盐焦磷酸测序分析FKBP5基因54个CpG位点的甲基化水平。
- 甲基化结果与GC替代、唾液皮质醇、24小时尿皮质醇、FKBP5多态性、医生指导的治疗调整及预定义临床GC暴露评分进行相关性分析。
- 甲基化水平进一步与64例 cortisol-producing adrenal adenomas(CPA)患者进行比较。
主要发现
- 甲基化水平与GC剂量、临床GC替代评分、唾液皮质醇及尿皮质醇水平均呈显著负相关。
- 被建议增加GC剂量的患者甲基化水平高于被建议减少或维持剂量的患者。
- AI患者的甲基化水平与CPA患者相似或更低。
临床怎么用
- FKBP5甲基化分析可能作为评估肾上腺功能不全患者GC替代治疗质量的潜在辅助指标。
- 临床可结合FKBP5甲基化、GC剂量及临床评分综合判断替代治疗是否充分。
局限性
- 本研究为探索性横断面分析,无法确立因果关系。
- 样本仅包括接受氢化可的松替代治疗的慢性原发性或继发性AI患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Methylation of FKBP5, a glucocorticoid (GC)-receptor co-chaperone, negatively correlates with cortisol levels in both healthy individuals and Cushing patients, potentially serving as an indicator of GC exposure. OBJECTIVE: We explored whether GC replacement correlates with FKBP5 methylation in patients with adrenal insufficiency (AI), aiming to assess the adequacy of therapy. METHODS: In an explorative cross-sectional analysis, we analyzed FKBP5 gene methylation at 54 CpG sites using bisulfite pyrosequencing in 120 patients with chronic primary (n = 72) and secondary (n = 48) AI on hydrocortisone replacement. Results were correlated with GC replacement, salivary cortisol, 24-hour urinary cortisol, FKBP5 polymorphisms, physician-guided therapy adjustments, and a predefined clinical score for assessment of GC exposure. Methylation levels were further compared with patients with cortisol-producing adrenal adenomas (CPA, n = 64). RESULTS: Significant negative correlations were found between methylation levels and GC dose, clinical GC replacement score, and salivary and urinary cortisol levels. Patients advised to increase their GC dose showed higher methylation levels than those recommended to reduce or maintain their dose. AI patients exhibited similar or lower methylation levels compared to those with CPA. CONCLUSION: The correlation between FKBP5 methylation status, GC replacement dose, and clinical evaluation of therapy suggests a dose-dependent effect of GC replacement on FKBP5 methylation. This encourages further research into the added value of FKBP5 methylation analysis in assessing the quality of replacement therapy. The lower methylation levels in AI compared to CPA suggest a potential impact of the cortisol peaks arising under conventional GC treatment on FKBP5-methylation.
引用
- Chifu I, Richter AL, Lippert J, et al. FKBP5 Methylation in Adrenal Insufficiency: New Insights Into Assessing the Quality of Glucocorticoid Replacement. J Clin Endocrinol Metab. 2026. PMID: 40608904. doi:10.1210/clinem/dgaf383
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。